Prostate Cancer and Supplementation With α-Tocopherol and β-Carotene: Incidence and Mortality in a Controlled Trial
Clicks: 3
ID: 300548
1998
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
0.6
/100
3 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #118 of 333 articles by views in JNCI Journal of the National Cancer Institute
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 333 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background: Epidemiologic studies have suggested that vitamin E and β-carotene may each influence the development of prostate cancer. In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, a controlled trial, we studied the effect of α-tocopherol (a form of vitamin E) and β-carotene supplementation, separately or together, on prostate cancer in male smokers. Methods: A total of 29 133 male smokers aged 50–69 years from southwestern Finland were randomly assigned to receive α-tocopherol (50 mg), β-carotene (20 mg), both agents, or placebo daily for 5–8 years (median, 6.1 years). The supplementation effects were estimated by a proportional hazards model, and two-sided P values were calculated. Results: We found 246 new cases of and 62 deaths from prostate cancer during the follow-up period. A 32% decrease (95% confidence interval [CI] = −47% to −12%) in the incidence of prostate cancer was observed among the subjects receiving α-tocopherol (n = 14 564) compared with those not receiving it (n = 14 569). The reduction was evident in clinical prostate cancer but not in latent cancer. Mortality from prostate cancer was 41% lower (95% CI = −65% to −1%) among men receiving α-tocopherol. Among subjects receiving β-carotene (n = 14 560), prostate cancer incidence was 23% higher (95% CI = −4%–59%) and mortality was 15% higher (95% CI = −30%–89%) compared with those not receiving it (n = 14 573). Neither agent had any effect on the time interval between diagnosis and death. Conclusions: Long-term supplementation with α-tocopherol substantially reduced prostate cancer incidence and mortality in male smokers. Other controlled trials are required to confirm the findings.
| Reference Key |
openalex_W2129528814
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Olli P. Heinonen, Leopold G. Koss, Demetrius Albanes, Philip R. Taylor, Anne M. Hartman, Brenda K. Edwards, Jarmo Virtamo, Jussi K. Huttunen, Jaason Haapakoski, Nea Malila, Matti Rautalahti, Samuli Ripatti, Hanna Mäenpää, Lasse Teerenhovi, Martti Virolainen |
| Journal | JNCI Journal of the National Cancer Institute |
| Year | 1998 |
| DOI |
10.1093/jnci/90.6.440
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.